Saltar al contenido
Merck
  • Novel gamma-aminobutyric acid rho1 receptor antagonists; synthesis, pharmacological activity and structure-activity relationships.

Novel gamma-aminobutyric acid rho1 receptor antagonists; synthesis, pharmacological activity and structure-activity relationships.

Journal of medicinal chemistry (2008-06-06)
Rohan J Kumar, Mary Chebib, David E Hibbs, Hye-Lim Kim, Graham A R Johnston, Noeris K Salam, Jane R Hanrahan
RESUMEN

Gamma-aminobutyric acid (GABA) analogues based on 4-amino-cyclopent-1-enyl phosphinic acid ( 34- 42) and 3-aminocyclobutane phosphinic acids ( 51, 52, 56, 57) were investigated in order to obtain selective homomeric rho 1 GABA C receptor antagonists. The effect of the stereochemistry and phosphinic acid substituent of these compounds on potency and selectivity within the GABA receptor subtypes was investigated. Compounds of high potency at GABA C rho 1 receptors ( 36, K B = 0.78 microM) and selectivity greater than 100 times ( 41, K B = 4.97 microM) were obtained. The data obtained was analyzed along with the known set of GABA C rho 1 receptor-ligands, leading to the development of a pharmacophore model for this receptor, which can be used for in silico screening.

MATERIALES
Product Number
Marca
Descripción del producto

Sigma-Aldrich
γ-Aminobutyric acid, ≥99%
Sigma-Aldrich
γ-Aminobutyric acid, BioXtra, ≥99%
Sigma-Aldrich
5-Aminovaleric acid, 97%